|
NY-ESO-1
antibody responses in 218 patients with prostate cancera.
|
Clinical
Stage
|
Antibody
Positive Sera
|
|
Proportion
|
Percentage
|
|
A
|
0/9
|
0%
|
|
B
|
0/28
|
0%
|
|
C
|
0/41
|
0%
|
|
D1
|
1/30
|
3.3%
|
|
D2
|
9/110
|
8.2%
|
|
Total
|
10/218
|
4.6%
|
aThe difference in the frequency of detection of NY-ESO-1 antibody between patients with metastasis (stages D1 and D2, 10/140) and without metastasis (stages A, B, and C, 0/78) was statistically significant (P<0.05). Statistical analysis was performed using Fisher's exact test.
|
